PlatformQ Health is pleased to announce the Health Education Journal, a peer reviewed journal focusing on the contributions that health education can make to personal and social well-being, health promotion and individual and public health, has published an article on a recent Platform Q Patient Education (PQPE) program for people with B-cell NHL.

The one-hour online video education program, produced in partnership with The Leukemia & Lymphoma Society (LLS), aimed to improve knowledge and self-efficacy on B-cell NHL and offer strategies to enhance quality of life through better disease and side effect management. The patient-focused online educational program was delivered at no charge for learners, and included live Q&A, learner polling and mixed quantitative and qualitative evaluation methods to gauge the level of impact.

Perceived Self-Efficacy in B-cell non-Hodgkin Lymphomas: Qualitative Outcomes in Patient-Directed Education provides insights from which educators should be encouraged to explore further through education, particularly with regard to strengthening self-efficacy for patients and caregivers. Educators should probe patients and caregivers about their experiences; concerns, values and beliefs; current self-care practices; and understand their motivations behind perceived self-efficacy.

We’re proud to be a leader in the field of educational design, delivery and outcomes, and are committed to sharing insights from our innovative programs to not only support the patients they were designed to educate, but others in our field to raise the bar on educational design.

Email us for more information about this program, article and how we’re changing the healthcare landscape by empowering patients through education.

The B-cell NHL patient education program was made possible through support provided by an educational grant from Pharmacyclics LLC, an Abbvie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and a grant from Genentech.



Perceived Self-Efficacy in B-cell non-Hodgkin Lymphomas: Qualitative Outcomes in Patient-Directed Education

Published in Health Education Journal March 24, 2018

Authors: Alexandra Howson, Thistle Editorial, LLC; Wendy Turell, PlatformQ Health Education LLC; Anne Roc, PlatformQ Health Education LLC


Objective: Perceived self-efficacy (PSE) is considered a foundation for effective self-care in the context of chronic disease and illness. In order to improve patient and caregiver knowledge about self-care in B-cell non-Hodgkin’s lymphoma (NHL), we designed and delivered an online, patient-focused education activity. Educational impact on PSE was evaluated using a mixed quantitative/qualitative methodology. We report here on the qualitative characteristics of self-efficacy.

Methods: We interviewed participants using open-ended questions based on a semi-structured interview guide. Interviews were audio-recorded and transcribed verbatim, and analysed using constant comparative method with software support (NVivo for Mac 11, QSR International).

Results: In all, 12 people diagnosed with B-cell NHL were interviewed. Descriptive analysis showed that participants were able to summarise key education messages about B-cell NHL presented in the programme. Key themes linked to self-care knowledge and practice included normalisation of self-care, learning the hard way, everyone is different and being prepared. Participants described four key strategies linked to the notion of ‘being prepared’: (1) asking questions, (2) building relationships with oncologists, (3) developing/maintaining a philosophy of life, and (4) connecting with others. These themes provide context for the experience of PSE and may also reflect beliefs that have implications for self-efficacy education.

Conclusions: Interview data affirm PSE as a foundation of self-care and identify beliefs underpinning PSE. A dominant belief of ‘being prepared’ was sustained by four strategies that education content reinforced. Educators can use these insights to strengthen self-efficacy education interventions for patients with B-cell NHL and other types of cancer.